• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Author Correction: Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.

作者信息

Lin Wanlong, Xu Jiabing, Liao Yufang, Lin Xiuxian, Yang Jianhui, Zhuang Wei

机构信息

Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China.

School of Pharmaceutical, Fujian University of Traditional Chinese Medicine, Fuzhou, China.

出版信息

Int J Clin Pharm. 2024 Jun;46(3):776. doi: 10.1007/s11096-024-01728-8.

DOI:10.1007/s11096-024-01728-8
PMID:38632205
Abstract
摘要

相似文献

1
Author Correction: Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.作者更正：评估与抗体药物偶联物相关的间质性肺疾病的安全问题：对美国食品药品监督管理局不良事件报告系统的真实世界药物警戒评估
Int J Clin Pharm. 2024 Jun;46(3):776. doi: 10.1007/s11096-024-01728-8.
2
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.评估抗体药物偶联物相关间质性肺病的安全性问题：FDA 不良事件报告系统的真实世界药物警戒评估。
Int J Clin Pharm. 2024 Jun;46(3):614-622. doi: 10.1007/s11096-023-01673-y. Epub 2023 Dec 15.
3
Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.药物性间质性肺疾病：一项对2004年至2021年美国食品药品监督管理局不良事件报告系统的真实世界药物警戒研究。
Ther Adv Drug Saf. 2024 Jan 27;15:20420986231224227. doi: 10.1177/20420986231224227. eCollection 2024.
4
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.阿贝西利在 FDA 不良事件报告系统中的比例失调分析：一项真实世界的上市后药物警戒评估。
Drug Saf. 2023 Sep;46(9):881-895. doi: 10.1007/s40264-023-01334-z. Epub 2023 Jul 7.
5
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.在真实世界中使用 risankizumab 的不良事件：FDA 不良事件报告系统的上市后药物警戒评估。
Front Immunol. 2023 May 15;14:1169735. doi: 10.3389/fimmu.2023.1169735. eCollection 2023.
6
Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system.评估戈沙妥珠单抗的真实世界安全性问题：使用美国食品药品监督管理局不良事件报告系统中的自发报告进行的不成比例分析。
Front Oncol. 2023 Oct 6;13:1276976. doi: 10.3389/fonc.2023.1276976. eCollection 2023.
7
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.一项基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库的关于阿米万他单抗相关心血管不良事件的真实世界药物警戒研究。
Sci Rep. 2024 Apr 25;14(1):9552. doi: 10.1038/s41598-024-55829-5.
8
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database.与曲妥珠单抗恩美曲妥珠单抗和曲妥珠单抗德鲁昔康治疗HER2阳性/突变恶性肿瘤相关的高风险不良事件：一项基于FAERS数据库的药物警戒研究。
Expert Opin Drug Saf. 2023 Jul-Dec;22(8):685-696. doi: 10.1080/14740338.2023.2204228. Epub 2023 Apr 20.
9
A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).基于 FDA 不良事件报告系统（FAERS）评估曲妥珠单抗相关不良反应的比例失调分析。
BMC Pharmacol Toxicol. 2023 Nov 13;24(1):62. doi: 10.1186/s40360-023-00702-w.
10
Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.考察米拉贝隆的安全性：对来自美国食品药品监督管理局不良事件报告系统（FAERS）数据库的真实世界药物警戒数据的分析。
Front Pharmacol. 2024 Mar 18;15:1376535. doi: 10.3389/fphar.2024.1376535. eCollection 2024.

引用本文的文献

1
Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer.在接受过大量治疗的卵巢癌患者队列中，使用mirvetuximab soravtansine的早期真实世界毒性经验与评估
Gynecol Oncol Rep. 2025 Apr 5;59:101738. doi: 10.1016/j.gore.2025.101738. eCollection 2025 Jun.